Interactions between digitoxin and some antiarrhythmic drugs

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Interactions

Background:

• Digitoxin is a cardiac glycoside used for heart conditions.
• Antiarrhythmic drugs like amiodarone, mexiletine, and propafenone are crucial in managing heart rhythm disorders.
• Understanding potential drug interactions is vital for patient safety and effective treatment.

Purpose of the Study:

• To investigate the pharmacokinetic interactions between digitoxin and three common antiarrhythmic drugs: amiodarone, mexiletine, and propafenone.
• To quantify the effect of these antiarrhythmic drugs on serum digitoxin concentrations in a rabbit model.

Main Methods:

• Experiments were conducted on rabbits to assess drug interactions.
• Serum digitoxin concentration was measured using the radioimmunoassay "Coat-A-Count" procedure.
• The impact of amiodarone, mexiletine, and propafenone on digitoxin levels was evaluated.

Main Results:

• Each of the three antiarrhythmic drugs significantly increased serum digitoxin levels, nearly doubling them compared to controls.
• Elevated digitoxin levels were observed within one hour of antiarrhythmic drug administration and persisted for 6-8 hours.
• A delayed increase in digitoxin levels was noted in some rabbits several days after initial drug administration, suggesting a complex interaction mechanism.

Conclusions:

• Amiodarone, mexiletine, and propafenone exhibit significant pharmacokinetic interactions with digitoxin in rabbits.
• These interactions lead to a substantial increase in serum digitoxin levels, potentially increasing the risk of toxicity.
• Further research is warranted to elucidate the underlying mechanisms of these drug interactions and their clinical implications.